MedTrace Logo

PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers

NCT06665425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-20

No results posted yet for this study

Summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

Epaminurad 9 mg

Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406

DRUG

C2406

Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406

Sponsors & Collaborators

Principal Investigators

  • Kyung-sang Yu, MD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2025-05-02
Completion
2025-09-04

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06665425 on ClinicalTrials.gov